Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer

In a phase II clinical trial, some patients with metastatic Merkel cell carcinoma whose cancer has progressed despite treatment with chemotherapy had durable tumor responses to the immunotherapy drug avelumab.

Cancer Currents: An NCI Cancer Research Blog